TollefsonMMCrowsonCSMcEvoyMTMaradit KremersH. Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol. 2010;62(6):979–987.
2.
MenterACordoroKMDavisD, et al.Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161–201. doi:10.1016/j.jaad.2019.08.049.
3.
RaychaudhuriSPGrossJ. A comparative study of pediatric onset psoriasis with adult onset psoriasis. Pediat Dermatol. 2000;17(3):174–178.
4.
TollefsonMMVan HoutenHKAsanteDYaoXMaradit KremersH. Association of psoriasis with comorbidity development in children with psoriasis. JAMA Dermatol. 2018;154(3):286–292.
5.
KimballABWuEQGuérinA, et al.Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol. 2012;67(4):651–7.e1–2. doi:10.1016/j.jaad.2011.11.948. PubMed PMID: 22243764.
6.
ColmanIPloubidisGBWadsworthMEJJonesPBCroudaceTJ. A longitudinal typology of symptoms of depression and anxiety over the life course. Biol Psych. 2007;62(3):1265–1271.
7.
TollefsonMMFinnieDMSchochJJEtonDT. Impact of childhood psoriasis on parents of affected children. J Am Acad Dermatol. 2017;76(2):286–289.e5.
8.
VarniJWGlobeDRHooperMBaumgartnerS. Health-related quality of life of pediatric patients with moderate to severe plaque psoriasis: comparisons to four common chronic diseases. Eur J Pediatr. 2012;171(3):485–492.
9.
BeattiePELewis-JonesMS. A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases. Brit J Dermatol. 2006;155(1):145–151.
10.
De JagerMEDe JongEMEversAWVan De KerkhofPCSeygerMM. The burden of childhood psoriasis. Pediatr Dermatol. 2011;28(6):736–737.
11.
RandaHTodbergTSkovLLarsenLSZachariaeR. Health-related quality of life in children and adolescents with psoriasis: a systematic review and meta-analysis. Acta Dermato-Venereol. 2017;97(5):555–563.
12.
OsierEWangASTollefsonMM, et al.Pediatric psoriasis comorbidity screening guidelines. JAMA Dermatol. 2017;153(7):698–704.
13.
Committee on Practice and Ambulatory Medicine, Bright Futures Periodicity Schedule Workgroup. 2017 recommendations for preventive pediatric health care. Pediatrics. 2017;139(4):e20170254.
14.
ChurtonSBrownLShinTMKormanNJ. Does treatment of psoriasis reduce the risk of cardiovascular disease?Drugs. 2014;74(2):169–182.
15.
GulliverWPYoungHMBachelezHRandellSGulliverSAl-MutairiN. Psoriasis patients treated with biologics and methotrexate have a reduced rate of myocardial infarction. J Cutan Med Surg. 2016;20(4):550–554.
16.
YangZSLinNNLiLLiY. The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: an updated meta-analysis. Clin Rev Allergy Immunol. 2016;51(2):240–247.
17.
HsuLArmstrongAW. Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response. Exp Rev Clin Immunol. 2013;9(10):949–958.
18.
ErgunTSeckin GencosmanogluDAlpsoyE, et al.Efficacy, safety and drug survival of conventional agents in pediatric psoriasis: a multicenter, cohort study. J Dermatol. 2017;44(6):630–634. doi:10.1111/1346-8138.13713. PubMed PMID:27943425.
19.
PallerASSiegfriedECPariserDM, et al.Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol. 2016;74(2):280–287e1-3.
20.
LandellsIMaranoCHsuMC, et al.Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73(4):594–603.
